Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoxia01:23

Hypoxia

Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of skin metastases of ovarian cancer: a novel therapeutic approach.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

The pathoanatomy of cancer: order in paradox.

EBioMedicine·2026
Same author

Peripheral immune network-directed dissection of lymph node regions (iLND): Novel surgical approach for the regional assessment and therapy of vulvar carcinoma.

Gynecologic oncology·2026
Same author

Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial.

Trials·2025
Same author

Hyperhydration of breast and skin cancers: effects on thermophysical tissue properties in clinical hyperthermia with water-filtered infrared-A radiation (wIRA) - an updated review.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·2025
Same author

Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer.

Head & neck·2025

Related Experiment Video

Updated: Jul 7, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Endogenous hypoxia markers: case not proven!

Arnulf Mayer1, Michael Höckel, Peter Vaupel

  • 1Institute of Physiology and Pathophysiology, University of Mainz, 55099 Mainz, Germany.

Advances in Experimental Medicine and Biology
|February 23, 2008
PubMed
Summary

Hypoxia in cancer is crucial, but commonly used "endogenous hypoxia markers" like HIF-1alpha, GLUT-1, and CA IX do not reliably reflect oxygen levels in patients. Their clinical use as hypoxia indicators is not supported by direct measurements.

More Related Videos

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

Induction and Testing of Hypoxia in Cell Culture
07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

Related Experiment Videos

Last Updated: Jul 7, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

Induction and Testing of Hypoxia in Cell Culture
07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

Area of Science:

  • Oncology
  • Cancer Pathophysiology
  • Biomarker Research

Background:

  • Hypoxia, or low oxygen, is a critical factor in solid tumors, driving therapy resistance, malignant progression, and poor prognosis.
  • Current knowledge relies on invasive O2-sensitive microsensors, limiting accessibility and application.
  • Hypoxia-inducible factor (HIF)-1alpha and downstream genes (GLUT-1, CA IX) are proposed as surrogate biomarkers for tumor oxygenation.

Purpose of the Study:

  • To investigate the clinical validity of proposed "endogenous hypoxia markers" (HIF-1alpha, GLUT-1, CA IX) as reliable indicators of tumor oxygenation.
  • To assess the correlation between these protein markers and direct pO2 measurements in specific tumor micro-areas, minimizing heterogeneity effects.

Main Methods:

  • Examined expression of HIF-1alpha, GLUT-1, and CA IX in tumor tissue micro-areas.
  • Correlated protein expression with direct pO2 measurements previously taken in the same micro-areas.
  • Minimized tumor heterogeneity influence by analyzing matched tissue samples.

Main Results:

  • No significant correlation was found between the expression levels of HIF-1alpha, GLUT-1, or CA IX and direct pO2 measurements.
  • The tight regulation observed in vitro does not translate to reliable clinical assessment of tumor oxygenation.
  • Discrepancies cannot be solely attributed to tumor heterogeneity.

Conclusions:

  • The term "endogenous hypoxia markers" is misleading for clinical oncology settings.
  • HIF-1alpha, GLUT-1, and CA IX are not reliable surrogates for direct oxygenation status assessment in patients.
  • Avoid using these markers to infer tumor oxygenation in clinical practice.